Mapi – Pharma Ltd.

General Information

We are a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex APIs, formulations and LCM products that target large markets. We are currently developing two LCM products for the treatment of multiple sclerosis (“MS”) and neuropathic pain. LCM products are new forms of marketed drugs which may offer advantages over existing formulations, such as improved patient compliance and reduced side effects, and allow extended patent and regulatory exclusivity of a marketed drug due to different formulations of product components, for example through depot or extended release formulations. Our LCM products seek to add value to products that are expected to go off-patent by integrating off-patent APIs with our formulations, resulting in a new final combination that is patentable.

Employees: 23
Founded: 2008
Contact Information
Address 16 Einstein St., P.O. Box 4113, Ness Ziona, IL 74140
Phone Number 972-73-712-1213
Web Address
View Prospectus: Mapi – Pharma Ltd.
Financial Information
Market Cap $118.2mil
Revenues $0.6 mil (last 12 months)
Net Income $-6.7 mil (last 12 months)
IPO Profile
Symbol MAPI
Exchange NASDAQ
Shares (millions): 3.1
Price range $15.00 - $17.00
Est. $ Volume $50.0 mil
Manager / Joint Managers JMP Securities
CO-Managers FBR/ Maxim Group
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change